Real-world experience of ocrelizumab in MS in the Turkish population: A singlecenter study
European Journal of Neurology
; 29:792, 2022.
Article
in English
| EMBASE | ID: covidwho-1978461
ABSTRACT
Background and aims:
Ocrelizumab is a humanized monoclonal antibody effective against CD20 positive B cells, approved by the FDA in 2017 to treat RRMS and PPMS. Despite these clinical studies, real-life data on ocrelizumab are limited.Methods:
We conducted a retrospective single-center study in Turkey. We obtained medical record data of patients who received at least one infusion of ocrelizumab and were followed for one year before and after treatment initiation.Results:
240 MS patients were included in our study (58.75%) RRMS, (21.25%) SPMS, and (20%) PPMS). Median follow-up was14 months (range, 4-42). 92% of all patients received another DMT or immunosuppressant (98.58% of RRMS, 100% of SPMS, 64.58% of PPMS) prior to treatment with ocrelizumab. ARR before and after initiation of ocrelizumab for both the RRMS and SPMS groups (RRMS, 0.8 vs. 0.1;SPMS, 0.44 vs. 0.04). The most common reason for switching to ocrelizumab was clinical and/or radiological activity. NEDA status at year one was achieved in 88.54% of the RRMS population, and disability progression was found at 12.77% in the same MS subtype. Despite premedication (97.91%), infusion-related reactions were reported in (15.41%). The most common infection in our study was COVID-19 infection (18.33%), followed by urinary and upper respiratory tract infections.Conclusion:
According to the first real-world preliminary study in the Turkish MS population using ocrelizumab, it is a well-tolerated, safe, and effective treatment agent in suppressing disease activity in both RRMS and progressive MS forms.
immunosuppressive agent; ocrelizumab; adult; conference abstract; controlled study; coronavirus disease 2019; disability; drug combination; drug therapy; female; follow up; human; human cell; infusion related reaction; major clinical study; male; medical record; multiple sclerosis; retrospective study; Turk (people); Turkey (republic); upper respiratory tract infection
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
European Journal of Neurology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS